DiaSorin, Inc. appears in FDA device records as the applicant for a single approved premarket application, P180047, covering the LIAISON QuantiFERON-TB Gold Plus assay, the LIAISON Control QuantiFERON-TB Gold Plus and the LIAISON QuantiFERON Software. The approval decision is dated November 26, 2019, with a Federal Register notice date of December 3, 2019, and the application was received December 10, 2018. The filing address is 1951 Northwestern Avenue, Stillwater, MN 55082-0285. The supplied filings link two records to this applicant, both under the PMA pathway. [2][7][8]

The approved assay and its components

The approved device is described in the FDA summary as an in vitro diagnostic test intended for the detection of interferon-gamma (IFN-gamma) in human lithium heparin plasma by chemiluminescence immunoassay (CLIA) using the LIAISON XL Analyzer. The approval covers the assay together with the LIAISON Control QuantiFERON-TB Gold Plus and the LIAISON QuantiFERON Software. The generic name recorded for the device is Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis, with product code NCD and device class 3. [2][7]

The assay is used with QIAGEN QuantiFERON-TB Gold Plus Blood Collection Tubes, which the FDA summary describes as containing a peptide cocktail simulating ESAT-6 and CFP-10. The LIAISON QuantiFERON Software applies an algorithm that combines the individual results associated with the four QIAGEN QuantiFERON-TB Gold Plus Blood Collection Tubes into a final result. [2]

Supplement S046 and the II product

A later supplement, P180047/S046, was received September 1, 2026 and decided September 24, 2026 under decision code OK30, a 30-Day Notice. The supplement type is recorded as a 30-Day Notice with the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the applicant's statement describes a manufacturing scale-up. The trade name on this record is LIAISON QuantiFERON-TB Gold Plus II. The advisory committee is Microbiology, and the expedited review flag is N. [1]

A DiaSorin press release dated February 24, 2026 states that the LIAISON QuantiFERON-TB Gold Plus II assay received PMA approval from the U.S. Food and Drug Administration and will be available in the United States at the end of March 2026. The same release attributes to the assay a 25% faster turnaround time compared to the previous generation assay and the ability for laboratories to test up to 75% more patients per hour. These are the publisher's stated claims about the product, not independently verified performance figures. [10]

What the filing record shows and does not show

The supplied collection contains two linked records, both on the PMA pathway, with decision counts of one OK30 and one APPR. The smaller record sample of two entries carries the same split, one OK30 and one APPR. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1][2]

The FDA summary lists no panel recommendation for P180047 and records the applicant as DiaSorin Inc. at the Stillwater address. That address is the filing address in FDA records and is not treated here as a headquarters designation. The public documents do not establish ownership, parent or brand relationships, customer lists, certifications or commercial availability beyond the press release statement about the II assay. [7][10]